Biomechemical effects of human α interferon in combination with α-difluoromethylornithine on human lymphoblastoid (DAIDI) cells in cultureROSENBLUM, M. G.Lymphokine research. 1991, Vol 10, Num 1-2, pp 83-87, issn 0277-6766, 5 p.Article

High performance liquid chromatographic analysis of the biological response modifier synthetic double-stranded RNA (dsRNA, Ampligen)ROSENBLUM, M. G; CHEUNG, L.Journal of liquid chromatography. 1986, Vol 9, Num 13, pp 2869-2877, issn 0148-3919Article

Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions : Recombinant Immunotoxins - The Next GenerationROSENBLUM, M. G; BARTH, S.Current pharmaceutical design (Print). 2009, Vol 15, Num 23, pp 2676-2692, issn 1381-6128, 17 p.Article

Differential activity of the 30-kD and the 100-kD forms of 2'-5'A_n synthetase induced by recombinant human interferon-α and interferon-γROSENBLUM, M. G; CHEUNG, L; KESSLER, D et al.Journal of interferon research. 1988, Vol 8, Num 3, pp 275-282, issn 0197-8357Article

Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cellsDONATO, N. J; ROTBEIN, J; ROSENBLUM, M. G et al.Journal of cellular biochemistry. 1991, Vol 46, Num 1, pp 69-77, issn 0730-2312Article

Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancerROSENBLUM, M. G; HORTOBAGYI, G. N.Cancer chemotherapy and pharmacology. 1986, Vol 18, Num 3, pp 247-251, issn 0344-5704Article

Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration routeROSENBLUM, M. G; RISO, A; GUTTERMAN, J. U et al.Cancer chemotherapy and pharmacology. 1986, Vol 16, Num 3, pp 273-276, issn 0344-5704Article

Synergistic antiproliferative activity of leukocyte interferon in combination with α-difluoromethylornithine against human cells in culture = Activité antiproliférative synergique de l'interféron de leucocyte associé à l'alphadifluorométhylornithine contre les cellules humains en cultureROSENBLUM, M. G; GUTTERMAN, J. U.Cancer research (Baltimore). 1984, Vol 44, Num 6, pp 2339-2340, issn 0008-5472Article

Time series analysis for system identification and diagnosticsLANDA, P. S; ROSENBLUM, M. G.Physica. D. 1991, Vol 48, Num 1, pp 232-254, issn 0167-2789, 23 p.Article

Effect of recombinant α-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of ¹³¹I-labeled monoclonal antibody CC49 in breast cancer : A phase II trialMACEY, D. J; GRANT, E. J; SCHLOM, J et al.Clinical cancer research. 1997, Vol 3, Num 9, pp 1547-1555, issn 1078-0432Article

Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-geloninMUJOO, K; CHEUNG, L; MURRAY, J. L et al.Cancer immunology and immunotherapy. 1995, Vol 40, Num 5, pp 339-345, issn 0340-7004Article

Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with γ-interferon and tumor necrosis factorO'BOYLE, K. P; COLLETTI, D; WIERNIK, P. H et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 18, Num 4, pp 221-230, issn 1067-5582Article

Positive and negative selection for tumor necrosis factor responsiveness reveals an inhibitory role for EGF receptor in TNF-induced antiproliferationNISHIKAWA, K; ROTBEIN, J; VIJJESWARAPU, D et al.Lymphokine and cytokine research. 1994, Vol 13, Num 1, pp 37-45, issn 1056-5477Article

Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin BWASAN, K. M; ROSENBLUM, M. G; CHEUNG, L et al.Antimicrobial agents and chemotherapy. 1994, Vol 38, Num 2, pp 223-227, issn 0066-4804Article

Phase I study of recombinant human interleukin-3 in patients with bone marrow failureKURZROCK, R; TALPAZ, M; ESTROV, Z et al.Journal of clinical oncology. 1991, Vol 9, Num 7, pp 1241-1250, issn 0732-183XArticle

Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanomaFRONTIERA, M; MURRAY, J. L; BUNN, P. A et al.Clinical nuclear medicine. 1989, Vol 14, Num 5, pp 357-366, issn 0363-9762Article

Characterization of human recombinant tumor necrosis factor-α antiproliferative effects on human cells in cultureROSENBLUM, M. G; DONATO, N. J; GUTTERMAN, J. U et al.Lymphokine research. 1988, Vol 7, Num 2, pp 107-117, issn 0277-6766Article

Interferon-induced changes in pharmacokinetics and tumor uptake of ¹¹¹In-labeled antimelanoma antibody 96.5 in melanoma patientsROSENBLUM, M. G; LAMKI, L. M; MURRAY, J. L et al.Journal of the National Cancer Institute. 1988, Vol 80, Num 3, pp 160-165, issn 0027-8874Article

Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary studyLOPEZ-BERESTEIN, G; FAINSTEIN, V; REUBEN, J et al.The Journal of infectious diseases. 1985, Vol 151, Num 4, pp 704-710, issn 0022-1899Article

Phase I study of ⁹⁰Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer : Effect of dose and EDTA coadministration on pharmacokinetics and toxicityROSENBLUM, M. G; VERSCHRAEGEN, C. F; MURRAY, J. L et al.Clinical cancer research. 1999, Vol 5, Num 5, pp 953-961, issn 1078-0432Article

Multifractallity in human heartbeat dynamicsIVANOV, P. C; NUNES AMARAL, L. A; GOLDBERGER, A. L et al.Nature (London). 1999, Vol 399, Num 6735, pp 461-465, issn 0028-0836Article

Autileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude miceXU, Y; XU, Q; ROSENBLUM, M. G et al.Leukemia. 1996, Vol 10, Num 2, pp 321-326, issn 0887-6924Article

Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins : role of lipid transfer proteinWASAN, K. M; MORTON, R. E; ROSENBLUM, M. G et al.Journal of pharmaceutical sciences. 1994, Vol 83, Num 7, pp 1006-1010, issn 0022-3549Article

Characterization of murine and humanized anti-CD33 gelonin immunotoxins reactive against myeloid leukemiasMCGRAW, K. J; ROSENBLUM, M. G; CHEUNG, L et al.Cancer immunology and immunotherapy. 1994, Vol 39, Num 6, pp 367-374, issn 0340-7004Article

Phase II radioimmunotherapy trial with ¹³¹I-CC49 in colorectal cancerMURRAY, J. L; MACEY, D. J; KASI, L. P et al.Cancer. 1994, Vol 73, Num 3, pp 1057-1066, issn 0008-543X, SUPConference Paper